www.mayflowerbio.com
Sales & Support: 314-485-5210

*

Favipiravir

Supplier:
Catalogue number:
10-4471-01
Size:
5 mg
Product is available in:
  • USA
  • Canada
$45.00 Shipping is calculated in checkout

Antiviral agent. In clinical use for influenza; blocks viral fusion to cell. Wang et al. Cell Res 30:269–271, Feb 4 2020, https://doi.org/10.1038/s41422-020-0282-0.

  • Datasheet:   view or download
  • Applications:Approved drug (Japan); in COVID-19 clinical trials
Product Type:

Biochemicals & reagents

CAS Number:

259793-96-9

Range:

1) Furuta et al. (2002), In Vitro and In Vivo Activities of Anti-Influenza Virus Compound T-705; Antimicrob. Agents Chemother., 46 977 2) Takahashi et al. (2003) In Vitro and In Vivo Activities of T-705 and Oseltamivir Against Influenza Virus; Antivir. Chem. Chemother., 14 235 3) Sleeman et al. (2010) In Vitro Antiviral Activity of Favipiravir (T-705) against Drug-Resistant Influenza and 2009 A(H1N1) Viruses; Antimicrob. Agents Chemother., 54 2517 4) Furuta et al. (2005) Mechanism of action of T-705 against influenza virus; Antimicrob. Agents Chemother., 49 981 5) Furuta et al. (2013) ), Favipiravir (T-705), a Novel Viral RNA Polymerase Inhibitor; Antiviral Res., 100 446 6) Dong et al. (2020) Discovering Drugs to Treat Coronavirus Disease 2019 (COVID-19); Drug Discov. Ther., 14 58 7) Tu et al. (2020) A Review of SARS-CoV-2 and the Ongoing Clinical Trials; Int.J.Mol.Sci., 21 E2657

Limit of Detection:

157.1

Storage Temperature:

-20°C (des.)

Additional Information:

Favipiravir is an inhibitor of Influenza viruses A, B, and C (IC50’s: A = 0.03-0.20 µg/mL H1N1, 0.01-0.30 H2N2, 0.08-0.48 H3N2, 0.14-0.15 H4N2, 0.24-1.60 H7N2, 0.20-0.82 H5N1, 0.35 H1N2; B = 0.04-0.09 µg/mL; C = 0.03-0.06 µg/mL) as well as strains resistant to adamantane-type antivirals, oseltamivir, and zanamivir (1,2,3). This compound displayed no cytotoxicity in a variety of cells and has been shown to selectively inhibit viral RNA-dependent RNA polymerase (4). It has also shown activity against other viruses including arena, phlebo, hanta, flavi, entero, alpha, respiratory syncytial, and noroviruses (5). It is in clinical trials for the treatment of SARS-CoV-2 (6,7).